VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.

Vertex (VERX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta ...

Vertex (VERX – Research Report), the Technology sector company, was revisited by a Wall Street analyst today. Analyst Chris Quintero from ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

The adjustment reflects Vertex's strong performance in its cystic fibrosis (CF) business, which has outperformed expectations. The company's recent financial results have demonstrated the ...

Several other equities analysts have also issued reports on the company. Jefferies Financial Group raised Vertex from a “hold” rating to a “buy” rating and raised their price objective for ...

Oct. 31, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, released new innovations, honored partners and ...

which may reflect concerns about the company’s ability to continue operations. Vertex has advantages when competing with Bluebird. In my view, the medicine has superior pricing and a superior ...

It’s been a busy few years for 32-year-old Oliver Smith. After leaving school, he honed his carpentry skills before moving to ...